




Searching News Database: synthetic biology
HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
HSMN NewsFeed - 10 Feb 2022
GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer
GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer
HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
HSMN NewsFeed - 8 Sep 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
HSMN NewsFeed - 30 Aug 2018
RootPath Raises $7 Million Seed Round led by Sequoia China to Accelerate Its Cancer Immunotherapy Programs
RootPath Raises $7 Million Seed Round led by Sequoia China to Accelerate Its Cancer Immunotherapy Programs
HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
HSMN NewsFeed - 30 Apr 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin(TM) Cytokines
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin(TM) Cytokines
HSMN NewsFeed - 27 Feb 2018
Senti Biosciences Secures $53 Million Series A to Build the Future of Gene and Cell-Based Therapies
Senti Biosciences Secures $53 Million Series A to Build the Future of Gene and Cell-Based Therapies
HSMN NewsFeed - 5 Dec 2017
Cocoon Biotech Appoints Dr. Annalisa Jenkins as Executive Chair of the Board
Cocoon Biotech Appoints Dr. Annalisa Jenkins as Executive Chair of the Board
HSMN NewsFeed - 14 Aug 2017
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
HSMN NewsFeed - 19 Jan 2016
Twist Bioscience Completes $61 Million Series D Financing And $20 Million Debt Facility
Twist Bioscience Completes $61 Million Series D Financing And $20 Million Debt Facility
HSMN NewsFeed - 18 Jan 2016
Michael Martino Named President and Chief Executive Officer of HemaFlo Therapeutics
Michael Martino Named President and Chief Executive Officer of HemaFlo Therapeutics
HSMN NewsFeed - 21 May 2015
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
HSMN NewsFeed - 24 Nov 2014
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
HSMN NewsFeed - 22 Jul 2014
Synlogic Secures $29.4 Million Series A Financing Led by Atlas Venture and New Enterprise Associates
Synlogic Secures $29.4 Million Series A Financing Led by Atlas Venture and New Enterprise Associates
HSMN NewsFeed - 6 Jan 2014
Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations
Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations
HSMN NewsFeed - 31 Dec 2013
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
HSMN NewsFeed - 6 Nov 2007
Sloning BioTechnology GmbH Raised EUR 4.7m in a First Closing of a Series E Equity Financing Round
Sloning BioTechnology GmbH Raised EUR 4.7m in a First Closing of a Series E Equity Financing Round